Search
for
Sort by
Research 361–390 of 1000+
- Upadacitinib for the Management of Alopecia Totalis and Subtotalis in Pediatric Patients: A Case Series
- Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib
- A new era for alopecia areata: New treatments and improved knowledge of the condition
- 455 Beyond Immunity: TEC and JAK3 Kinase Activation in Melanocytes Drives Inflammation in Vitiligo
- Case report: Psoriasiform eczema with immune-mediated comorbidities treated with upadacitinib
- Tofacitinib in the Management of Alopecia Universalis
- Effectiveness and safety of baricitinib in severe alopecia areata: 48‐week results
- Exploring the Use of Topical Tofacitinib in Pediatric Alopecia Totalis
- Central nervous system demyelination associated with tofacitinib use in alopecia areata: A case report and literature review
- Therapeutic Response of Alopecia Areata‐Associated Nail Changes to Baricitinib
- Clinical Trial Eligibility in Real‐World Alopecia Areata Patients Treated With Baricitinib
- Oclacitinib Treatment and Surgical Management in a Case of Periocular Eosinophilic Furunculosis and Vasculitis with Secondary Eyelid Fusion in a Diabetic Cat
- Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024
- Research Progress in Chronic Autoimmune Urticaria
- Alopecia Areata in Sub-Saharan Africa: A Scoping Review Protocol on Epidemiology, Clinical Presentation, Burden, Treatment, and Evidence Gaps.
- Treatment of Refractory Segmental Vitiligo and Alopecia Areata in a Child with Upadacitinib and NB-UVB: A Case Report
- Alopecia universalis following human papillomavirus vaccine administration: a case report
- Turning JAK STATic, a peek into the future of dermatology therapeutics
- Treatment of alopecia areata with JAK inhibitors: a review of the literature
- El papel de los inhibidores de JAK en la alopecia areata: revisión de la literatura
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- JAK inhibitors and alopecia areata
- JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
- The Role of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo: A Review article
- Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative review
- Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis
- SPT6 maintains epidermal homeostasis by inhibiting an NF-κB-positive feedback loop to prevent excessive inflammation
- Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata
- Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata
- Topical tofacitinib solution for the treatment of alopecia areata affecting eyelashes